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Abstract
Background
Mycolactone, the macrolide exotoxin produced byMycobacterium ulcerans, causes exten-
sive tissue destruction by inducing apoptosis of host cells. In this study, we aimed at the pro-
duction of antibodies that could neutralize the cytotoxic activities of mycolactone.
Methodology/Principal Findings
Using the B cell hybridoma technology, we generated a series of monoclonal antibodies
with specificity for mycolactone from spleen cells of mice immunized with the protein conju-
gate of a truncated synthetic mycolactone derivative. L929 fibroblasts were used as a
model system to investigate whether these antibodies can inhibit the biological effects of
mycolactone. By measuring the metabolic activity of the fibroblasts, we found that anti-
mycolactone mAbs can completely neutralize the cytotoxic activity of mycolactone.
Conclusions/Significance
The toxin neutralizing capacity of anti-mycolactone mAbs supports the concept of evaluat-
ing the macrolide toxin as vaccine target.
Author Summary
Mycolactones A/B (also simply referred to as mycolactone) are macrolide exotoxins pro-
duced byMycobacterium ulcerans, the causative agent of the neglected tropical skin dis-
ease Buruli ulcer (BU). The potent cytotoxic and anti-inflammatory activities of
mycolactones lead to severe destruction of the subcutaneous fat tissue with minimal
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inflammation in the core of the lesion. Due to the lipid-like nature of mycolactones, the
production of antibodies against these molecules has so far been unsuccessful. By using
the classical approach of fusing immortal cells with spleen cells of mice immunized with a
protein conjugate of a truncated non-toxic synthetic mycolactone, we were able to gener-
ate hybridoma cells producing mycolactone-specific monoclonal antibodies. Mammalian
cell-based cytotoxicity assays demonstrated that these antibodies have neutralizing activity
and can fully block the cytotoxic activity of mycolactone, resulting in survival of the target
cells. These findings support the concept to target mycolactone by a vaccine. Furthermore,
the anti-mycolactone antibodies may represent useful tools for BU diagnostics
development.
Introduction
Mycobacterium ulcerans, the causative agent of the neglected tropical skin disease Buruli ulcer
(BU), produces the exotoxin mycolactone, which is responsible for the formation of chronic
necrotizing skin lesions [1, 2]. Early diagnosis followed by rapid initiation of the currently rec-
ommended treatment with rifampicin and streptomycin [3] is crucial to avoid massive tissue
destruction and long-term disabilities.
Mycolactones consist of a 12-membered macrolide core structure, a short C-linked upper
side chain (comprising C12–C20) and a longer C5-O-linked lower polyunsaturated acyl side
chain. Mycolactones produced by differentM. ulcerans lineages differ in the structure of the
lower side chain, but are otherwise conserved [4]. For the lower side chain variations in length,
the number of double bonds and the number and localization of hydroxyl groups have been
described. WhileM. ulcerans strains may produce mixtures of several mycolactone species, the
composition of these pools seems to be highly conserved for a particularM. ulcerans lineage
[5]. Strains belonging to the genomically monomorphic classical African lineage produce the
most toxic variant, mycolactone A/B [6]. This lineage is responsible for> 95% of the BU cases
reported worldwide [7].
Mycolactone-deficientM. ulceransmutants are less virulent and intradermal injection of
the toxin in animal models is sufficient to induce the formation of BU-like lesions [4, 8]. Since
mycolactones play such a central role in the pathogenesis of BU [1, 2, 9], they may represent a
suitable target for both vaccine development and passive immunotherapy. However, due to
their lipid-like nature, as well as their cytotoxic and immunosuppressive [10–12] activities,
attempts to raise antibody responses against mycolactones have failed so far. While extracts
fromM. ulcerans cultures have been the only source of mycolactones for a long time, highly
defined synthetic mycolactones have become available more recently [6, 13, 14], greatly facili-
tating experimental work with these compounds. Here, we generated mycolactone specific
immune-sera and monoclonal antibodies (mAbs) by immunizing mice with a protein conju-
gate of a non-toxic synthetic truncated mycolactone derivative.
Materials and Methods
Ethics statement
Animal experiments performed were approved by the animal welfare committee of the Canton
of Basel (authorization number 2375) and were conducted in compliance with the Swiss Ani-
mal Welfare Act (TSchG), Animal Welfare Ordinance (TSchV), and the Animal Experimenta-
tion Ordinance (TVV).
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Preparation of mycolactone stock solutions
Natural mycolactones A/B, C and F as well as variants PG-157, PG-165, PG-182 and core PG-
119 were produced as described previously [6, 14]. The synthesis of biotin-conjugate PG-204
and the immunogen PG-203 will be described elsewhere. All compounds were HPLC-purified.
For biological testing 0.5 mg/ml mycolactone stock solutions were made by adding cell culture
grade DMSO (Sigma).
Extracts of mycolactone were prepared using mycobacterial pellets from cultures of strains
isolated from lesions of Cameroonian BU patients (S1013, S1019, S1047). Briefly, 1 ml of a
chloroform-methanol solution (2:1, v/v) was added to the individual pellets. Bacteria were
resuspended by vortexing and lipids were extracted by incubating the samples shaking at RT
for 2 h. Then, 200 μL ddH2O were added to induce a phase separation. After vigorous vortex-
ing, the samples were centrifuged for 10 min and the lower organic phase was transferred to a
fresh tube. Samples were placed in a Speedvac (Thermo Scientific) for complete drying. 50 μL
acetone were added and after an additional spin for 10 min at maximal speed, the acetone-solu-
ble lipid fraction containing mycolactones was separated from the precipitate, collected in
fresh tubes and again dried using the Speedvac device. For biological testing, the acetone-solu-
ble lipid fractions were resuspended in cell culture grade DMSO (Sigma).
Immunization of mice
2 mg of mycolactone PG-203 were coupled to 2 mg of BSA using the Imject EDC BSA spin kit
(Pierce). NMRI mice (Harlan Laboratories) were immunized thrice in 3 week intervals by sub-
cutaneous injection of 40 μg of the coupled product emulsified in Sigma adjuvant. Serum anti-
body titers against the biotinylated mycolactone derivative PG-204 were tested by ELISA.
Based on the ELISA results, one NMRI mouse was selected to receive a final intravenous injec-
tion of 40 μg of the PG-203-BSA conjugate without adjuvant. Three days after this last booster
dose, hybridoma cell lines were generated as described below.
Generation of monoclonal antibodies
Mice were euthanized and the spleen was aseptically removed. Spleen tissue was mashed and the
cells were fused with PAI myeloma cells in the presence of PEG 1500 (Roche) [15]. Mother cell
line culture supernatants were tested by ELISA for the presence of anti-mycolactone antibodies
and positive lines were cloned by limiting dilution. mAbs were purified from hybridoma culture
supernatants by affinity chromatography using a HiTrap Protein A HP column (GE Healthcare).
Isotypes were determined by ELISA with isotype specific reagents (SouthernBiotech).
ELISA
NeutrAvidin Coated High Capacity plates (Thermo Scientific) were incubated with 2 μg/ml
biotinylated mycolactone PG-204 in PBS for 2 h at 37°C in the dark. The PG-204 solution was
then replaced by SuperBlock T20 (TBS) blocking buffer (Thermo Scientific). Plates were incu-
bated for 1 h at 37°C in the dark, then washed twice with PBS 0.05% Tween. Hybridoma super-
natants were applied to the plates for 2 h at 37°C in the dark. Plates were washed four times
with PBS 0.05% Tween. Bound anti-mycolactone antibodies were detected using an Alkaline
Phosphatase (AP) conjugated goat anti-mouse IgG antibody (Sigma) diluted 1:20,000 in block-
ing buffer. The plate was incubated for 1 h at 37°C in the dark, and then washed four times
with PBS 0.05% Tween. Development was done using the Alkaline Phosphatase Yellow
(pNPP) Liquid Substrate System (Sigma). The absorbance was measured at 405 nm with a
microplate reader (Tecan Sunrise) and the values were plotted against the concentration.
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Competition ELISA
For competition experiments Maxisorp plates were coated with mAbs (10 μg/ml) o/n and then
blocked with SuperBlock T20 (TBS) blocking buffer (Thermo Scientific) for 1 h at 37°C. After
washing twice with PBS 0.05% Tween, serial dilutions of synthetic mycolactone compounds
were added and incubated for 2 h at 37°C in the dark. DMSO served as negative control. Subse-
quently biotinylated PG-204 was added (100 pg/ml) without washing steps and incubated for
an additional 30 min. Plates were washed four times with PBS 0.05% Tween. Bound PG-204
was detected with alkaline phosphatase coupled streptavidin (SouthernBiotech) after 45 min
incubation at 37°C. The development was performed as described above.
Metabolic activity assays
Murine L929 fibroblasts were cultivated at 37°C and 5% CO2 in RPMI medium (Gibco) supple-
mented with 10% FCS (Sigma), 2 mM glutamine (Gibco) and 0.05 mM β-mercaptoethanol
(Gibco). For the assay, L929 cells (24,000 per well) were seeded in 24-well plates (Falcon) and
incubated o/n at 37°C. Medium was aliquoted and mixed with 15 ng/ml synthetic mycolactone
A/B, mycolactone core PG-119 or varying amounts of mycolactone extracts. Dependent on the
assay format, fixed or increasing concentrations of anti-mycolactone antibody or isotype-
matching control antibody (JD4.1) were added and incubated for 10 min. The medium in
the 24-well plates was aspirated and replaced by 500 μl medium containing the mycolactone-
antibody mixes. After an incubation period of 48 h, Resazurin solution (Sigma) was added to
the wells (10% v/v), and the cells were further incubated for 2 hours at 37°C and 5% CO2. In
order to quantitatively assess metabolic activities, the fluorescence intensities were measured
using a SpectraMax Gemini XS (Molecular Devices), and the obtained values were normalized
for the DMSO control. The experiments were set up in duplicates and performed at least three
times. Fluorescence intensities were plotted against the log concentration of neutralizing
antibody.
Surface Plasmon Resonance (SPR) analyses
SPR experiments were performed on Biacore 3000 or T200 instruments (GE Healthcare, Upp-
sala, Sweden) at 25°C. HEPES buffer (10 mMHEPES, 150 mMNaCl, 0.05% (w/v) Tween 20,
pH 7.4) was used as running buffer and flow rates of 5 or 50 μl min-1 were used for the immobi-
lization and binding assays, respectively. Anti-mycolactone mAbs were captured on the chip
surface by primary antibodies. First, the primary antibody was immobilized covalently on the
carboxymethyldextran surface of a CM5 sensor (GE Healthcare, Uppsala, Sweden). The car-
boxymethyl groups of the dextran sensor surface were activated for 600 s with a mixture of 0.2
M (3-dimethylaminopropyl)carbodiimide (EDC) and 0.05 M N-hydroxysuccinimide (NHS).
Next, the primary antibody, a rat anti-mouse IgG1 mAb (SouthernBiotech, AL, USA) diluted
in 10 mM borate buffer (pH 8.2) to a concentration of 20 μg/ml was contacted for 120 s with
the activated sensor surface to achieve antibody densities of 8000–12000 RUs. Subsequently,
remaining active ester molecules on the sensor were deactivated by applying 1M ethanolamine
(pH 8.0) for 420 s. Anti-mycolactone mAbs were diluted in running buffer to a concentration
of 200 nM and captured by the primary antibodies to achieve antibody densities in the range of
2500–4000 RUs.
Mycolactone derivative PG-204 was titrated over the surfaces with the immobilized anti-
mycolactone mAbs. Association and dissociation phases were monitored for 240 and 3600 s,
respectively. Bound mycolactone was washed out from the surface in regeneration steps (injec-
tion of 10 mM glycine, pH 2.2).
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Results
Generation of mycolactone-specific mAbs
For the generation of mycolactone specific antibody responses we have immunized mice with
PG-203, a truncated and non-cytotoxic mycolactone derivative coupled to BSA via a diethylene
glycol-based linker replacing the C5-O-linked polyunsaturated acyl side chain (Fig 1A).
Mice had developed strong anti-mycolactone IgG responses after two immunizations with
the adjuvanted protein carrier conjugate and a third immunization boosted the immune
response further (Fig 2).
Spleen cells of mice immunized with the PG-203-BSA conjugate were used for the genera-
tion of hybridomas producing anti-mycolactone mAbs by conventional B cell hybridoma tech-
nology. Hybridoma cell culture supernatants were screened by ELISA using NeutrAvidin
plates coated with PG-204 (Fig 1C), a biotinylated derivative of PG-203. Screening led to
the identification of 12 hybridoma clones producing the anti-mycolactone mAbs JD5.1 to
JD5.12. All twelve mAbs were of the IgG1 isotype and showed binding to PG-204, but not to
PG-183 (Fig 3), a mycolactone derivative biotinylated at the C-linked short upper side chain
(Fig 1D).
The fine specificity of mAbs was further characterized by competition ELISAs. Plates were
coated with anti-mycolactone mAbs and the biotinylated mycolactone derivative PG-204 was
added as reporter molecule. By titrating in increasing amounts of synthetic natural variants of
mycolactone (mycolactone A/B, C and F), a truncated synthetic derivative (PG-119), or deriva-
tives with modifications in the C-linked upper side chain (PG-157, PG-165 and PG-182) we
were able to assess the fine specificity of the binding. All mAbs showed very similar fine speci-
ficity patterns (depicted for the prototype mAb JD5.1 in Fig 4). As predicted from the structure
of the immunizing truncated mycolactone derivative PG-203, the presence/absence or detailed
Fig 1. Synthetic mycolactone derivatives used for the generation and detection of mycolactone specific antibody responses. PG-
203 (A) was conjugated to BSA via the amino group on its diethylene glycol-based linker and the carrier protein conjugate was used for the
immunization of mice. PG-204 (C) and PG-183 (D) are biotinylated mycolactone derivatives used for analytical purposes. Unmodified
synthetic mycolactone A/B (B) was used as effector molecule in cytotoxicity assays.
doi:10.1371/journal.pntd.0004808.g001
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structure of the C5-O-linked polyunsaturated lower acyl side chain had no significant effect on
binding to the mAbs. PG-119, a truncated mycolactone lacking the lower fatty acid acyl side
chain was thus as efficient as the complete mycolactones A/B, C and F in competing with the
reporter molecule PG-204 (Fig 4).
In contrast, modifications in the C-linked upper side chain had major effects on the effi-
ciency as competitor. The more complex the modifications were, the less competition was
observed (Fig 4), suggesting that the upper side chain along with the mycolactone core consti-
tutes part of the epitope of the mAbs.
For all mAbs, addition of a terminal hydroxyl group in PG-165 reduced binding and a
major extension of the upper side chain in PG-182 abrogated competition completely. Only for
PG-157, a derivative with a slight extension of the upper side chain, a difference in the competi-
tion pattern was observed, with only mAbs 5.9 and 5.11 showing slight inhibition (the differ-
ence is depicted for the prototype mAbs JD5.1 and JD5.11 in Fig 5).
Fig 2. Mice immunized with the adjuvanted PG-203-BSA conjugate developed a boostable anti-
mycolactone IgG response.Displayed are average anti-mycolactone IgG titers of three mice after the
second and third immunization in comparison to pooled pre-immune sera. Titers were determined by ELISA
using NeutrAvidin plates coated with PG-204.
doi:10.1371/journal.pntd.0004808.g002
Fig 3. The anti-mycolactonemAbs JD5.1 to JD5.12 bind to PG-204, but not to PG-183. The biotinylated mycolactone derivatives PG-204
and PG-183 were bound to NeutrAvidin plates and incubated with serial dilutions of the mAbs. Bound anti-mycolactone mAbs were detected
using alkaline phosphatase-conjugated goat anti-mouse IgG antibodies.
doi:10.1371/journal.pntd.0004808.g003
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In Surface Plasmon Resonance (SPR) analyses the anti-mycolactone mAbs immobilized
on the surface of the sensor chip showed very tight binding to the biotinylated mycolactone
derivative PG-204. The association and dissociation rate constants could not be precisely deter-
mined as the dissociation rate constants were outside the limitation of the measuring technol-
ogy (Fig 6). For some of the mAbs (JD5.1, JD5.2, JD5.5, JD5.8 and JD5.10) dissociation rates
were extremely slow with the monitored dissociation rate constant outside the limitation of the
instrument resolution (koff< 10
−6 s-1). Also the other mAbs showed slow dissociation rates
with an estimated koff approximating the resolution limit (koff between 10
−5 s-1 and 10−6 s-1).
Measurements with mycolactone A/B failed, most likely due to aggregation of the more hydro-
phobic complete toxin molecule.
Fig 4. Effect of structural modifications of mycolactone on antibody binding. Competition ELISAs were performed by coating microtiter
plates with the mAbs and pre-incubation with serial dilutions of mycolactone A/B, natural mycolactone variants harboring modifications in the
lower fatty acid acyl side chain (mycolactone C and mycolactone F), a truncated core molecule without O-linked lower side chain (PG-119) or
derivatives containing substitutions in the upper side chain (PG-165, PG-157 and PG-182). Biotinylated PG-204 was subsequently added and
its binding was detected by using alkaline phosphatase-conjugated streptavidin as reporter. Detailed results with all tested mycolactone
derivatives are shown for mAb 5.1 as example.
doi:10.1371/journal.pntd.0004808.g004
Antibody-Mediated Neutralization of Mycolactone Cytotoxicity
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004808 June 28, 2016 7 / 12
Toxin neutralizing activity of the anti-mycolactone mAbs
To investigate whether mycolactone specific antibodies can neutralize the cytotoxic activity of
the macrolide toxin, L929 fibroblasts were incubated with synthetic mycolactone A/B at the
cytotoxic concentration of 15 ng/ml (20 nM) in the presence of serially diluted anti-mycolac-
tone mAbs. After 48 h of incubation, the metabolic activity of the L929 cells was assessed by
performing Resazurin-based assays. While all anti-mycolactone mAbs showed toxin-neutraliz-
ing activity, the molar ratio of antibody versus mycolactone required for neutralization varied
(Fig 7). While several mAbs neutralized the toxin completely already at a molar ratio of 2.5,
only partial inhibition was observed at a ratio of 12.5 for the least active mAb JD5.2 (Fig 7).
The morphology of L929 cells treated with mycolactone and sufficient amounts of toxin-neu-
tralizing antibody was indistinguishable from that of DMSO-treated control cells. In contrast,
Fig 5. Two types of reactivity patterns. All mAbs displayed a similar fine specificity pattern, except for mAbs 5.9 and 5.11, which, in
contrast to the other mAbs, showed inhibition with PG-157, a derivative with a slightly extended upper side chain (the difference is depicted
for the prototype mAbs JD5.1 and JD5.11).
doi:10.1371/journal.pntd.0004808.g005
Fig 6. SPR analysis of anti-mycolactonemAbs. Anti-mycolactone mAbs were captured on the chip
surface by primary antibodies. The biotinylated mycolactone derivative PG-204 was then titrated over the
surface and association and dissociation phases were monitored for 240 and 3600 s, respectively. Prototype
titration binding curves for two selected mAbs (JD5.8 and JD5.10) are shown. Titration of both antibodies was
performed up to 500 nM with a dilution factor of 2.
doi:10.1371/journal.pntd.0004808.g006
Antibody-Mediated Neutralization of Mycolactone Cytotoxicity
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004808 June 28, 2016 8 / 12
cells treated with no or insufficient amounts of antibody showed characteristic signs of apopto-
sis. The anti-mycolactone mAbs also neutralized the mycolactones produced by cultivatedM.
ulcerans bacteria (S1 Fig).
Competition with the truncated non-toxic mycolactone derivative PG-119 lacking the lower
acyl side chain (Fig 1) reconfirmed specificity of the neutralizing activity. At a concentration of
40 ng/ml (86 nM), PG-119 completely abrogated the toxin neutralizing activity of mAb JD5.1
(Fig 8).
Fig 7. Toxin neutralizing activity of anti-mycolactonemAbs. L929 fibroblasts were incubated with 15 ng/ml (20 nM) synthetic mycolactone
A/B and mAbs were added in different molar ratios of excess antibody versus mycolactone. After 48 h, the metabolic activity of fibroblasts was
measured. The graph shows mean values across duplicate samples, and the error bars represent the standard deviation of three independent
experiments. As control, the isotype-matched antibody JD4.1 was used.
doi:10.1371/journal.pntd.0004808.g007
Fig 8. Inhibition of antibodymediated neutralization by addition of the non-toxic mycolactone core
variant PG-119. L929 cells were treated with a mix of 15 ng/ml (20 nM) synthetic mycolactone A/B and a 2.5
fold molar excess of the anti-mycolactone mAb JD5.1. Serial dilutions of PG-119 were added to the mix,
starting with a PG-119 concentration of 40 ng/ml (86 nM). As control, the isotype-matched antibody JD4.1
was used. After 48 h, the metabolic activity of fibroblasts was measured and plotted against the concentration
of PG-119. The graph shows mean values across duplicate samples, and the error bars represent the
standard deviation of three independent experiments.
doi:10.1371/journal.pntd.0004808.g008
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Discussion
Here we describe for the first time the production of antibodies against mycolactone, the main
virulence factor ofM. ulcerans. So far, no antibodies against mycolactone were detected in
mice or humans infected withM. ulcerans [16] and attempts by several groups to generate
mycolactone-specific antisera or mAbs by immunization with protein carrier conjugates of
chemically modified mycolactone extracted fromM. ulcerans cultures have failed before. This
may be related to residual cytotoxicity of the conjugates and killing of B cells that incorporated
them after binding to their mycolactone specific surface immunoglobulins. With the availabil-
ity of synthetic mycolactone derivatives it has become possible to both generate highly defined
protein conjugates for immunization and to develop reliable assays for the detection of myco-
lactone specific antibodies. For immunization we have used here a carrier conjugate of a myco-
lactone derivative in which the C5-O-linked polyunsaturated acyl side chain was replaced by a
diethylene glycol-based linker. Since the structure of the lower side chain is crucially important
for the cytotoxic activity of mycolactone [6], this compound (PG-203) was expected to be non-
cytotoxic, even if it were released from the carrier protein after massive uptake by mycolactone
specific B cells.
Coupling of the synthetic mycolactone derivative to the carrier protein BSA ensured T cell
help for the mycolactone specific B cells, leading to clonal expansion, affinity maturation and
isotype switching. As a result high anti-mycolactone IgG titers were elicited in mice already by
two immunizations with the adjuvanted PG-203 carrier conjugate. All mAbs generated from
the immunized mice were of the IgG1 subclass and exhibited high affinity and specificity for
mycolactone. Competition assays indicated that the epitope recognized includes elements of
the upper short side chain that is C-linked to the core structure. As expected [6], structural var-
iation or absence of the lower C5-O-linked lower polyunsaturated acyl side chain had no effect
on antibody binding. All mAbs exhibited high affinity binding with very slow dissociation rates
which did not permit exact determination of the affinity constant by SPR analyses.
Currently, there is no highly effective vaccine against the major mycobacterial diseases
tuberculosis, leprosy and BU available. BCG, originally developed against tuberculosis, may
offer only partial and short-lasting [17] or no [18] protection against BU. Attempts to develop
a subunit vaccine [16, 19, 20] or a live vaccine based on mycolactone-deficientM. ulcerans [21]
had limited success. All twelve mycolactone-specific mAbs generated here showed, albeit to a
varying degree, the capacity to neutralize mycolactone and to rescue mammalian cells from
apoptosis in an in vitro assay. This supports the concept to target mycolactone in BU vaccine
design. Both prophylaxis and therapy with toxin-neutralizing antibodies and active immuniza-
tion with toxoids are highly successful strategies for protection against pathogens such as diph-
theria or tetanus bacteria that produce a toxin as key virulence factor.
M. ulcerans has evolved from a common ancestor withM.marinum by acquisition of a plas-
mid designated pMUM, which encodes the polyketide synthases required for mycolactone bio-
synthesis [22–24]. None of the other pathogenic mycobacteria produce a macrolide toxin,
making mycolactone an excellent target for the development of a species specific diagnostic
test. Such an assay would also have potential for the monitoring of treatment success by mea-
suring mycolactone levels in fine needle aspirates from closed BU lesions or swab samples
from ulcerative lesions. The availability of the mAbs described here is enabling the develop-
ment of a competition assay for the quantification of mycolactone. If non-competing mAbs
specific for the lower part of the core and the lower side chain can be generated, development
of an antigen capture assay may become possible.
Taken together, the first successful generation of mycolactone specific antibodies described
in this report will stimulate development of new tools for research and control of BU.
Antibody-Mediated Neutralization of Mycolactone Cytotoxicity
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004808 June 28, 2016 10 / 12
Supporting Information
S1 Fig. Neutralization of mycolactone extracts by antibody JD5.1. From mycobacterial iso-
lates S1013, S1019 and S1047, acetone-soluble lipids were extracted and added to L929 cells
and incubated with mAb JD5.1. As control, the isotype-matched mAb JD4.1 was used. After 48
h, the metabolic activity of fibroblasts was measured. One representative of at least three inde-
pendent experiments is shown.
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